BACKGROUND: The aim of this study was to examine the quality of life (QoL) of the live donor renal transplant (LDRTx) recipients pre- and post-transplantation and correlate with their pre-transplant (pre-Tx) dialysis status and immunosuppressive regimens post-transplantation (post-Tx). MATERIAL/ METHODS: 57 LDRTx recipients and 38 healthy individuals as controls participated in the study. The Kidney Transplant Questionnaire (KTQ) and the Medical Outcome Survey Short Form 36 (SF-36) questionnaires were used to assess QoL. RESULTS: The post-Tx scores in all SF-36 dimensions were significantly higher in the LDRTx recipients, but remained lower than that of the control group. However, in the KTQ, all dimensions except Appearance (p=0.035), significantly increased post-Tx Patients transplanted pre-emptively and those on tacrolimus-based immunosuppressive drugs had significantly better QoL. CONCLUSIONS: LDRTx significantly improved QoL, which was best with preemptive transplantation and tacrolimus-based immunosuppressive regimens.
BACKGROUND: The aim of this study was to examine the quality of life (QoL) of the live donor renal transplant (LDRTx) recipients pre- and post-transplantation and correlate with their pre-transplant (pre-Tx) dialysis status and immunosuppressive regimens post-transplantation (post-Tx). MATERIAL/ METHODS: 57 LDRTx recipients and 38 healthy individuals as controls participated in the study. The Kidney Transplant Questionnaire (KTQ) and the Medical Outcome Survey Short Form 36 (SF-36) questionnaires were used to assess QoL. RESULTS: The post-Tx scores in all SF-36 dimensions were significantly higher in the LDRTx recipients, but remained lower than that of the control group. However, in the KTQ, all dimensions except Appearance (p=0.035), significantly increased post-Tx Patients transplanted pre-emptively and those on tacrolimus-based immunosuppressive drugs had significantly better QoL. CONCLUSIONS:LDRTx significantly improved QoL, which was best with preemptive transplantation and tacrolimus-based immunosuppressive regimens.
Authors: Yiman Wang; Marc H Hemmelder; Willem Jan W Bos; Jaapjan D Snoep; Aiko P J de Vries; Friedo W Dekker; Yvette Meuleman Journal: Nephrol Dial Transplant Date: 2021-12-02 Impact factor: 5.992